Form D · Biotechnology
Talapo Therapeutics, Inc.
La Jolla, CA · CIK 0001725002
Offering snapshot reported Dec 12, 2017 · SEC filing
- Reported sold
- $100K Offering amount: $800K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 30, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 12, 2017 | Initial | $99,999 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-300507
Source: Form D, filed Dec 12, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Craig Harding | Director |
| Erik Martinez Hackert | Director |
| Davorka Messmer | Director, Executive |
| Neil Senturia | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2223 Avenida De La Playa Suite 206
La Jolla, CA, 92037
La Jolla, CA, 92037